Advertisement
Advertisement
ZVRA
Zevra Therapeutics, Inc. Common Stock
11.56
USDSponsored
-0.32
-2.69%
Aug 07, 15:59 UTC -4
Closed
After-Market
11.53
-0.03
-0.29%
ZVRA Earnings Reports
Positive Surprise Ratio
ZVRA beat 22 of 43 last estimates.
51%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$37.08M
/$0.12
Implied change from Q2 26 (Revenue/ EPS)
-6.51%
/-52.00%
Implied change from Q3 25 (Revenue/ EPS)
+42.26%
/-1300.00%
Zevra Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 05, 2026, ZVRA reported earnings of 0.25 USD per share (EPS) for Q2 26, beating the estimate of 0.10 USD, resulting in a 128.31% surprise. Revenue reached 39.66 million, compared to an expected 34.56 million, with a 14.76% difference. The market reacted with a +12.82% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of 0.12 USD, with revenue projected to reach 37.08 million USD, implying an decrease of -52.00% EPS, and decrease of -6.51% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
electroCore, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.33
Surprise
+23.40%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
FAQ
What were Zevra Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Zevra Therapeutics, Inc. Common Stock reported EPS of $0.25, beating estimates by 128.31%, and revenue of $39.66M, 14.76% above expectations.
How did the market react to Zevra Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 12.82%, changed from $10.53 before the earnings release to $11.88 the day after.
When is Zevra Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Zevra Therapeutics, Inc. Common Stock's next earnings report?
Based on 7
analysts, Zevra Therapeutics, Inc. Common Stock is expected to report EPS of $0.12 and revenue of $37.08M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement